Extendicare Inc.

TSX:EXE.TO

Medical - Care Facilities

Healthcare
$28.81 +2.61%

+$0.86 today

Market cap
$2.74B
Beta
1.16
P/E (TTM)
26.4
EPS (TTM)
$1.28
Dividend yield
1.51%
52W Low $12.12High $35.62

Volume 0.86M

Average 0.34M

EXE.TO Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Extendicare Inc.TSX: EXE.TO

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development remains negative

Q2 FY2026 research & development was CA$0, compared with CA$0 a year earlier. Trailing-twelve-month research & development was CA$0.

Context

  • Research & development amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly research & development holds near CA$0 or moves back toward the trailing-twelve-month quarterly average of CA$0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
CA$0— QoQ
Last fiscal yearDec 2025
CA$0— YoY
LTMJun 2026
CA$0— YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Research & Development history

CAD · from the income statement

Latest · FY2025
0 CAD
Year-over-year change
—

Research & Development vs competitors

How EXE.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Research & development amounts to 0.0% of revenue for EXE.TO, versus a peer median of 0.0%.
EXE.TO Competitors
Research & Development for EXE.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRON.TOCronos Group Inc.LTM Mar 2026$3.68M USD-8.7%-30.1%2.3%
TLRY.TOTilray Brands, Inc.LTM Feb 2026$246.09K USD-61.8%-42.8%0.0%
EXE.TOExtendicare Inc.LTM Jun 2026CA$0 CAD——0.0%
SIA.TOSienna Senior Living Inc.LTM Sep 2026CA$0 CAD——0.0%
WELL.TOWELL Health Technologies Corp.LTM Mar 2026CA$0 CAD-100.0%—0.0%
DR.TOMedical Facilities CorporationLTM Mar 2026$0 USD——0.0%
CRRX.TOCareRx CorporationLTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding EXE.TO) —-61.8%-36.4%0.0%

Competitors are the stored peer set for EXE.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.17B1.22B1.3B1.47B1.66B
Cost of Revenue1.05B1.14B1.14B1.3B1.46B
Gross Profit115.61M76.83M167.62M168M199.59M
Gross Margin9.9%6.3%12.8%11.5%12.0%
Research & Development00000
Selling, General & Admin69.79M51.08M55.84M1.2B1.36B
Operating Expenses52.43M50.78M55.84M56.94M61.22M
Depreciation & Amortization38.57M32.12M32.23M33.34M37.25M
EBITDA75M49.33M98.63M155.27M175.61M
EBITDA Margin6.4%4.0%7.6%10.6%10.6%
Operating Income49.71M20.99M62.96M111.21M138.37M
Operating Margin4.3%1.7%4.8%7.6%8.3%
Interest Income1.87M5.02M6.19M7.04M5.73M
Interest Expense22.45M21.7M21.6M21.1M19.23M
Other Income / Expenses(35.72M)(25.48M)(18.16M)(11.35M)(8.26M)
Income Before Tax13.99M(4.5M)44.8M99.86M130.1M
Pre-Tax Margin1.2%-0.4%3.4%6.8%7.8%
Income Tax Expense6.48M15K10.82M24.65M33.45M
Net Income11.5M69.55M33.98M75.21M96.66M
Net Margin1.0%5.7%2.6%5.1%5.8%
EPS (Basic)0.130.850.400.971.13
EPS (Diluted)0.130.850.400.861.11
Weighted Avg Shares89.99M89.01M84.99M84.22M85.4M
Weighted Avg Shares (Diluted)100.9M89.01M84.99M95.36M86.84M

Extendicare Inc.

TSX:EXE.TO

Intrinsic Alpha fair value

Locked

Current Price

$28.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.